We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Biopharma Driving Surge in Contract Pharmaceutical Manufacturing

By LabMedica International staff writers
Posted on 12 Mar 2009
The pharmaceutical manufacturing industry is evolving as new technologies such as biologics and sterile manufacturing take over, requiring specialized production and processes, according to a new market report. More...


The sheer numbers of biologics in the pipeline are impelling drug makers to outsource specialized production rather than build new plants. Medical market research publisher Kalorama Information (New York, NY, USA), a market research company, estimates the market for contract manufacturing of prescription drugs will exceed US$30 billion in 2008, which represents an increase of 10% from the prior year, which represents an increase of 10% from the prior year.

The two fastest growing sectors in the contract manufacturing market are biomanufacturing and secondary manufacturing, according to market analyst from Kalorama. The expansion of biotech-derived protein and peptide drugs, antibiotics, and chemotherapeutic agents administered as sterile injectable drugs is creating a robust business for sterile secondary contract manufacturing, as these processes are often not included in the core competency of pharmaceutical and biotech drug makers.

While the primary contract manufacturing organization (CMO) sector, which includes active pharmaceutical ingredients and chemical intermediates, is plagued by overcapacity, reduced drug output, and a highly competitive landscape, the secondary CMO sector is enjoying strong growth, due in large part to the great demand for sterile manufacturing. As a result, many CMOs are expanding their capabilities to include biopharmaceutical facilities. They are also turning to smaller emerging drug companies for new business and must, therefore, change their business model, as their needs are different and they outsource many activities major drug companies do internally, according to at Kalorama market analysts.

"Cost is important, but so are speed and flexibility,” said Bruce Carlson, publisher of Kalorama Information. "Pharma companies that want to pursue specialized niches, complicated drug delivery, and/or biologic drugs will have to contact a CRO [contract research organization].”

Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of research services.

Related Links:

Kalorama Information




Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
New
Clinical Informatics Platform
CLARION™
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Copyright © 2000-2026 Globetech Media. All rights reserved.